jacqueline marvel PhD Immunology

Course and current status


- Habilitation à diriger des recherches University Claude Bernard, Lyon1 (1997)

- PhD Université Libre de Bruxelles (1986)

- Candidat Ingénieur Agronome Faculté des Sciences Agronomiques de Gembloux (1978)

Research and Management Experience
- Research Director class I (DR1), group leader (2008-present).

- Head of the INSERM research Unit 851, Lyon (2007-2012)

- Director of the animal house facility "Plateau de Biologie Expérimentale de la Souris", RIO 2001, ENS-Lyon (2002-2006)

- Research Director class II (DR2), (2000-2008).

- Directeur-adjoint of the INSERM research Unit 503, Lyon (2001-2006)

- Chargé de Recherche class I C.N.R.S (1994-1999)

- Professeur-associé ENSL, Chaire Marcel Mérieux, Director of the Cellular Immunology team, LBMC, ENSL (1993-94)

- Research Fellow Leukemia Research Fund, Institute of Cancer Research, Chester Beatty Laboratories, London, UK (1991-93)

- Research Fellow, I.C.R.F., Tumour Immunology Unit, Director: Prof.N.A.Mitchison, University College London. London, U.K (1986-1991).

Expertise, consultancy

- Member advisory committee: ARC regional (1997-2002)

- Member advisory committee: LNLCC National (2001-2005)

- Vice-president  "comité régional d'éthique pour l'expérimentation animale" (2002-2007)

- Member advisory committee: ARC CN1 national (2005-2011)

- Regular reviews for funding agencies ANR, FRM, Welcome Trust… or Journals EJI, J. Immunol…

Independent Expert FP7, DG recherche, UE (2008)

Scientific summary

Jacqueline Marvel is the head of the team « cytotoxic lymphocytes and memory CD8 T cells. This team includes 3 researchers with a permanent position, 1 post-doctoral fellow, 2 PhD students, 1 master student, 3 engineers and 1 technician. J. Marvel has a long-standing expertise in the field of memory CD8 T cells biology. Her group has demonstrated that memory CD8 T cells have an increased response potential in terms of proliferation (Pihlgren et al J. Exp. Med 1996), IFNg production (Pihlgren et al Int. Immunol. 1999) and CCL5 production (Walzer T. J. Immunol 2003) compared to naïve CD8 T cells.  They have also shown that improved memory CD8 T cells functions are regulated by cytokine such as IL-4 (Marçais et al J. Immunol 2006). Her recent contribution to the field is the identfication and characterization of a novel subset of memory CD8 T cells (TIM) (F.-M Mbitikon-Kobo J. Immunol 2009). Her team, in collaboration with the team of Nathalie Bonnefoy-Bérard, has demonstrated that TLR2 is expressed by CD8 T cells and acts as a costimulatory molecule that regulates naïve and memory CD8 activation ( Cottalorda et al E.J.I. 2006, Cottalorda et al E.J.I. 2009). Her team is also interested in the mechanisms of antigen cross-presentation to CD8 T cells. They have recently demonstrated, for the first time, that newly derived CD8+ DC are unable to cross-present dead-cells-derived antigen unless they are first treated with inflammatory signals such as the cytokine GM-CSF or PAMPS (de Brito et al J. Immunol 2010).

Image d’exemple